LEVETIRACETAM
PRODUCT IDENTIFICATION
102767-28-2
TOXICITY
H.S. CODE
Levetiracetam; (S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide;
(S)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; (alphaS)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; Levetiracetamum; Keppra; (alphaS)-alpha-Ethyl-2-oxo-1-pyrrolidineacetamide; 2(S)-(2-Oxopyrrolidin-1-yl)butyramide;
N1([C@H](C(=O)N)CC)C(=O)CCC1
CLASSIFICATION
Antiepileptic,
EXTRA NOTES
PHYSICAL AND CHEMICAL PROPERTIES
118 ~ 119 C
Insoluble
REFRACTIVE INDEX
NFPA RATINGS
Health hazard: 2, Flammability: 0, Physical hazards: 0
AUTOIGNITION
FLASH POINT
EXTERNAL LINKS & GENERAL DESCRIPTION
Drug Information Portal (U.S. National Library of Medicine) - Levetiracetam
PubChem Compound Summary - Levetiracetam
Drug Bank - Levetiracetam
KEGG (Kyoto Encyclopedia of Genes and Genomes) - Levetiracetam
http://www.ebi.ac.uk/ - Levetiracetam
http://www.ncbi.nlm.nih.gov/ - Levetiracetam
http://www.sigmaaldrich.com/Biochem/physiol Actions: Levetiracetam is a pyrrolidine with antiepileptic activity. Stereoselective binding of levetiracetam was confined to synaptic plasma membranes in the central nervous system with no binding occurring in peripheral tissue. Levetiracetam inhibits burst firing without affecting normal neuronal excitability, which suggests that it may selectively prevent hyper-synchronization of epileptiform burst firing and propagation of seizure activity.
http://www.ajhp.org/
Summary. Levetiracetam, an antiepileptic drug (AED), was first approved as an adjunctive therapy for the treatment of partial epilepsy in adults. It is currently being used in the treatment of multiple seizure disorders, including generalized tonic–clonic; absence; myoclonic, especially juvenile myoclonic; Lennox-Gastaut syndrome; and refractory epilepsy in children and adults. Data are emerging on possible uses of levetiracetam outside the realm of epilepsy because of its unique mechanisms of action. There is preliminary evidence about the efficacy of levetiracetam in the treatment of different psychiatric disorders, including anxiety, panic, stress, mood and bipolar, autism, and Tourette’s syndrome. The most serious adverse effects associated with levetiracetam use are behavioral in nature and might be more common in patients with a history of psychiatric and neurobehavioral problems.
Conclusion. Levetiracetam is an effective AED with potential benefits in other neurologic and psychiatric disorders. The benefit–risk ratio in an individual patient with a specific condition should be used to determine its optimal use. Levetiracetam’s use in nonepileptic conditions is not recommended until more data become available from larger trials.
N03AX:
|
Product |
CAS RN. |
|
Sultiame |
61-56-3 |
Phenacemide |
63-98-9 |
Lamotrigine |
84057-84-1 |
Felbamate |
25451-15-4 |
Topiramate |
97240-79-4 |
Gabapentin |
60142-96-3 |
Pheneturide |
90-49-3 |
Levetiracetam |
102767-28-2 |
Zonisamide |
68291-97-4 |
Pregabalin |
148553-50-8 |
Stiripentol |
49763-96-4 |
Lacosamide |
175481-36-4 |
Carisbamate |
194085-75-1 |
Retigabine |
150812-12-7 |
Perampanel |
380917-97-5 |
Beclamide |
501-68-8 |
APPEARANCE
IDENTIFICATION
passes Test IR, HPLC
ASSAY
98.0 ~102.0%
-89º ~ -91º
LOSS ON DRYING
0.5% max
R-FORM
0.5% max
HEAVY METALS
20ppm max
IMPURITY
1.0% max (total impurity), 0.4% max (Individual Impurity)
HAZARD OVERVIEW
Harmful by ingestion., Irritant
GHS
Warning
PICTOGRAMS
HAZARD STATEMENTS
H302-H319
P STATEMENTS
P305 + P351 + P338